Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Inozyme Pharma is a clinical-stage biopharmaceutical company developing therapies targeting rare diseases affecting bone mineralization and blood vessel function. Its lead product, INZ-701, is designed to increase PPi and adenosine levels to treat conditions like ENPP1 and ABCC6 deficiencies, calciphylaxis, and related disorders. The company focuses on innovative biologics, leveraging its expertise in the PPi-Adenosine pathway to address unmet medical needs in systemic calcification and vascular diseases.
This description was generated via AI from an annual report. Updated about 1 year ago.